Sun Pharma Advanced Research Co Ltd
NSE:SPARC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
112.01
206.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Gross Margin
Sun Pharma Advanced Research Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
S
|
Sun Pharma Advanced Research Co Ltd
NSE:SPARC
|
46.7B INR |
64%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
83%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
496.6B USD |
68%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
259.2B CHF |
74%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
208.2B CHF |
76%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
251.4B USD |
79%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
82%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
143.2B USD |
75%
|
Sun Pharma Advanced Research Co Ltd
Glance View
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-07-18. The firm is engaged in the business of research and development (R&D) of pharmaceutical products to meet unmet medical needs in the areas of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCE), new biological entities (NDDS) and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its NDDS includes Wrap Matrix technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology, which is useful to develop controlled-release tablets. The firm has developed Elepsia XR, using Wrap Matrix technology. Lipexelle technology for ophthalmic formulations. The company has developed Xelpros, a BAK-free latanoprost eye drops developed using Lipexelle technology. Xelpros is commercialized by the Company’s partner in the United States. The company developed PDP-716 eye drops for the treatment of glaucoma based on its TearAct technology.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Sun Pharma Advanced Research Co Ltd's most recent financial statements, the company has Gross Margin of 63.9%.